Ben Taylor

Ben is an associate in Goodwin’s Technology and Life Sciences group specializing in venture capital financings and M&A transactions. Ben advises clients on a broad range of corporate matters, with a particular focus on emerging growth companies and venture capital investors. Ben advises clients through every stage of the corporate life cycle.

• Sound Bioventures on its investment in the recent £19 million financing round of Theolytics. Theolytics is developing oncolytic viral therapy for the treatment of ovarian cancer.

Prior to joining Goodwin, Ben was head of the Corporate & Securities team at Hopin, Europe's then fastest growing start up. During his time at Hopin, Ben guided the business through $950 million of financings and acquired five technology companies.

Prior to joining Hopin, Ben spent five years in the London office of Cooley, another leading law firm in the venture and M&A space where he focused on tech M&A, private equity, and venture financings.